saplin

ITI Pharma and Healthcare Fund

ITI Pharma and Healthcare Fund (Direct, Growth): saplin Score 8.2/10 (Strong) among 126 Sectoral/Thematic funds. 3Y return 20.7% a year vs 14.7% category median, expense ratio 0.86%. Returns that beat most peers, but a short or weak manager record. NAV ₹20.64 on 11 Nov 2026.

Loading the full analysis…

Questions about ITI Pharma and Healthcare Fund

What is the expense ratio of ITI Pharma and Healthcare Fund?

The Direct plan's total expense ratio is 0.86% a year, against a median of 1.20% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages ITI Pharma and Healthcare Fund?

Animesh Singh (since 8 May 2026); Nilay Dalal (since 8 May 2026).

What are the top holdings of ITI Pharma and Healthcare Fund?

Sun Pharmaceutical Industries 11.67%, Divi's Laboratories 9.98%, Apollo Hospitals Enterprise 5.62%, Dr. Reddy's Laboratories 5.23%, Torrent Pharmaceuticals 4.58% of the portfolio, as of 31 Oct 2026.

What returns has ITI Pharma and Healthcare Fund given?

1 year: 17.4% (category median 4.6%); 3 years: 20.7% a year (category median 14.7%); 5 years: 15.6% a year (category median 12.1%). Past returns do not predict future ones.

How big is ITI Pharma and Healthcare Fund?

About ₹266 cr (AMFI's average for the latest quarter).

How does ITI Pharma and Healthcare Fund score?

8.2 out of 10 (Strong) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on ITI Pharma and Healthcare